Naftazone
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Naftazone is a naphthoquinone derivative indicated in the treatment of varicose veins, hemorrhoids, and superficial thrombophlebitis.
- Generic Name
- Naftazone
- DrugBank Accession Number
- DB13680
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 215.212
Monoisotopic: 215.069476542 - Chemical Formula
- C11H9N3O2
- Synonyms
- Naftazona
- Naftazone
- Naftazonum
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Chronic venous insufficiency (cvi) •••••••••••• •••••• Treatment of Hemorrhoids •••••••••••• •••••• Treatment of Superficial thrombophlebitis •••••••••••• •••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Take with or without food.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Mediaven / Mediavene
Categories
- ATC Codes
- C05CX02 — Naftazone
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Naphthalenes
- Sub Class
- Not Available
- Direct Parent
- Naphthalenes
- Alternative Parents
- Aryl ketones / Semicarbazones / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aromatic homopolycyclic compound / Aryl ketone / Carbonyl group / Hydrocarbon derivative / Ketone / Naphthalene / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 15B0523P5L
- CAS number
- 15687-37-3
- InChI Key
- TZGBBMBARSFJBG-UKTHLTGXSA-N
- InChI
- InChI=1S/C11H9N3O2/c12-11(16)14-13-9-6-5-7-3-1-2-4-8(7)10(9)15/h1-6H,(H3,12,14,16)/b13-9+
- IUPAC Name
- {[(2E)-1-oxo-1,2-dihydronaphthalen-2-ylidene]amino}urea
- SMILES
- NC(=O)N\N=C1/C=CC2=CC=CC=C2C1=O
References
- General References
- TITCK Product Information: Mediaven (naftazone) oral tablets [Link]
- External Links
- ChemSpider
- 4698034
- 31475
- ChEBI
- 134890
- ChEMBL
- CHEMBL2106794
- ZINC
- ZINC000018163569
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 10 mg Tablet Oral 30 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.31 mg/mL ALOGPS logP 1.2 ALOGPS logP 1.3 Chemaxon logS -2.8 ALOGPS pKa (Strongest Acidic) 11.64 Chemaxon pKa (Strongest Basic) -1.2 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 84.55 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 59.76 m3·mol-1 Chemaxon Polarizability 21.2 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-014l-1900000000-29d0babc3af4e9abbc2b Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014l-4090000000-9465057679fe1413a8bb Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00dl-0900000000-3d1db2f15ba1ea14c32b Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00ke-6940000000-8853e288c7ad9bf27ea2 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-0900000000-5828c962712c670b5536 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-00kf-2900000000-e46b5278345d2af0a0e5 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0udi-0900000000-5fd98534e26d519275a5 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 141.59929 predictedDeepCCS 1.0 (2019) [M+H]+ 143.99486 predictedDeepCCS 1.0 (2019) [M+Na]+ 149.98949 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:46 / Updated at May 29, 2021 18:12